Skip to main content
SpringerLink
Log in

Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis

  • Chapter
Helicobacter pylori

Abstract

There have been hundreds of studies involving various combinations of antimicrobial and antisecretory drugs, to identify the ‘best’ method of curing Helicobacter pylori infection. In some instances (e.g. the combination of a proton-pump inhibitor and amoxycillin) the results have been extremely variable; in others the results have been relatively consistent (e.g. a proton-pump inhibitor, clarithromycin, and metronidazole)1-4. This chapter attempts to address why this occurs. Early experiments showed that H. pylori infection requires more than one drug; reliable treatment required combinations of antibiotics or combinations of antimicrobials and antisecretory agents. H. pylori is a mucosal infection, and as such is ‘outside’ the body. What has been learned regarding the treatment of other bacterial infections of mucosal surfaces should, in general, apply to the treatment of H. pylori infections. However, the slow growth of H. pylori may explain (in part), the need to treat with multiple agents as compared with other enteric infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. van der Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter. 1996;1:6–19.

    Article  PubMed  Google Scholar 

  2. Unge P, Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol. Suppl. 1996;215:74–81.

    Article  CAS  Google Scholar 

  3. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol. 1997;43:223–43.

    Article  PubMed  CAS  Google Scholar 

  4. Börsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, editors. Pharmacology of Peptic Ulcer Disease. Handbook of Experimental Pharmacology, Vol. 99. Berlin: Springer-Verlag; 1991:107–48.

    Chapter  Google Scholar 

  5. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493–6.

    PubMed  CAS  Google Scholar 

  6. Graham DY, de Boer WA, Tytgat GN. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996;91:1072–6.

    PubMed  CAS  Google Scholar 

  7. Go MF, Graham DY. Determinants of clinical outcome of H. pylori infection: duodenal ulcer. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht: Kluwer; 1994:421–8.

    Google Scholar 

  8. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11(Suppl. 1)43–53.

    Article  PubMed  CAS  Google Scholar 

  9. Megraud F, Lehn N, Lind T et al. The MACH2 study. Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome. Gastroenterology. 1997;112:A216 (abstract).

    Google Scholar 

  10. Bazzoli F, Zagari RM, Fossi S et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6:773–7.

    Article  Google Scholar 

  11. Graham DY, Lew GM, Ramirez FC, Genta RM, Klein PD, Malaty HM. A non-metronidazole triple therapy for eradication of Helicobacter pylori infection — tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993;7:111–13.

    Article  PubMed  CAS  Google Scholar 

  12. de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol. 1996;22:313–16.

    Article  PubMed  Google Scholar 

  13. Graham DY, Evans DG. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis. 1990;12(Suppl. 1):S68–72.

    Article  PubMed  Google Scholar 

  14. Graham DY, Lew GM, Evans DG, Evans DJ, Jr, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991;115:266–9.

    PubMed  CAS  Google Scholar 

  15. Stone GG, Shortridge D, Versalovic J et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother. 1997;41:712–14.

    PubMed  CAS  Google Scholar 

  16. Versalovic J, Shortridge D, Kibler K et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996;40:477–80.

    PubMed  CAS  Google Scholar 

  17. Versalovic J, Osato MS, Spakovsky K et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother. 1997;40:283–6.

    Article  PubMed  CAS  Google Scholar 

  18. Midolo PD, Turnidge J, Lambert JR, Bell JM. Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis. 1995;21;135–40.

    Article  PubMed  CAS  Google Scholar 

  19. Dore MP, Nana A, Carta Metal. Effect of amoxicillin resistance on the therapy of Helicobacter pylori infection. Gastroenteroloy. 1998;114:A108.

    Google Scholar 

  20. Dore MP, Graham DY, Sepulveda A. PBP-D, a novel penicillin-binding protein, is involved in amoxicillin resistance in Helicobacter pylori. Gastroenterology. 1998;114:A109.

    Google Scholar 

  21. Midolo PD, Korman MG, Turnidge JD, Lambert JR. Helicobacter pylori resistance to tetracycline [letter]. Lancet. 1996;347:1194–5.

    Article  PubMed  CAS  Google Scholar 

  22. Dore MP, Are B, Carta M, Mura I, Maida A, Realdi G. Antibiotic resistant H. pylori are extremely common in Sardinia. Gastroenterology. 1998;114:A108.

    Google Scholar 

  23. Graham DY. A reliable cure for Helicobacter pylori infection? Gut. 1995;37:154–6.

    Article  PubMed  CAS  Google Scholar 

  24. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10:1029–33.

    Article  PubMed  CAS  Google Scholar 

  25. Dammann HG, Folsch UR, Hahn EG, Klor HU, Kirchner T, Kist M. 7 vs 14 day treatment with pantoprazole, clarithromycin and metronidazole for cure of H. pylori infection in duodenal ulcer patients. Gut. 1998;41(Suppl. 1)A95 (abstract).

    Google Scholar 

  26. Katicic M, Presecki V, Marusic M et al. Eradication of H. pylori with two triple-therapy regimens of 7, 10 and 14 days duration. Gut. 1998;41(Suppl. 1):A100 (abstract).

    Google Scholar 

  27. Krause R, Pruitt R, Lukasik N, Thomas J, Fennerty B. 10 vs. 14 day triple therapy with lansoprazole (Prevacid), amoxicillin and clarithromycin in the eradication of Helicobacter pylori (Hp). Gut. 1998;41(Suppl. 1):A103 (abstract).

    Google Scholar 

  28. Bardhan KD, Bayerdörffer E, Delchier J et al. H. pylori (Hp) eradication with omeprazole (0), metronidazole (M) and amoxicillin (A): the impact of drug dosing and resistance on efficacy-the Homer story. Gastroenterology. 1998;114:A65.

    Article  Google Scholar 

  29. Lamouliatte H, Forestier S, Perie F Lansoprazole (Lanso) 30 mg or 60 mg combined with two antibiotics [amoxicillin (Amox) and clarithromycin (Clari)] to eradicate Helicobacter pylori (H pylori). Gastroenterology. 1998;114:A194.

    Google Scholar 

  30. Gotz JM, Veenendaal RA, Veselic M, Bernards S, Lamers CB. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Scand J Gastroenterol Suppl. 1995;212:34–7.

    Article  PubMed  CAS  Google Scholar 

  31. Yousfi MM, El-Zimaity HM, Cole RA, Genta RM, Graham DY. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli’s triple therapy). Aliment Pharmacol Ther. 1996;10:119–22.

    Article  PubMed  CAS  Google Scholar 

  32. Miederer S. Triple ranitidine therapy in Helicobacter pylori infection. Recommendation for effective, safe and cost effective combination for Helicobacter pylori eradication. Fortschr Med. 1996;114:460–2.

    PubMed  CAS  Google Scholar 

  33. Kihira K, Satoh K, Saifuku K et al. Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11:511–14.

    Article  PubMed  CAS  Google Scholar 

  34. Lazzaroni M, Bargiggia S, Porro GB. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1997;92:649–52.

    PubMed  CAS  Google Scholar 

  35. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308–12.

    Article  PubMed  CAS  Google Scholar 

  36. Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy - ranitidine,clarithromycin, and metronidazole — for cure of Helicobacter pylori infection [letter]. Am J Gastroenterol. 1995;90:168–9.

    PubMed  CAS  Google Scholar 

  37. Tham TC, Collins JS, Molloy C, Sloan JM, Bamford KB, Watson RG. Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. Ulster Med J. 1996;65:131–6.

    PubMed  CAS  Google Scholar 

  38. Furuta T, Ohashi K, Kamata T et al. CY2C19 genotype status and dual therapy with omeprazole and amoxicillin for eradication of Helicobacter pylori and peptic ulcer healing. Gastroenterology. 1998;114:Al27.

    Google Scholar 

  39. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62:384–91.

    Article  PubMed  CAS  Google Scholar 

  40. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol. 1997;32:24–7.

    Article  CAS  Google Scholar 

  41. Zala G, Schwery S, Giezendanner S et al. Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole amoxicillin. Schweiz Med Wochenschr. 1996;126:153–8.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. Y. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. P. Dore
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada

    Richard H. Hunt (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Gastroenterology and Hepatology, Academic Medical Centre, 9 Meibergdreef, 1105 AZ, Amsterdam, The Netherlands

    Guido N. J. Tytgat (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Graham, D.Y., Dore, M.P. (1998). Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobacter pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4882-5_44

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4882-5_44

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6046-2

  • Online ISBN: 978-94-011-4882-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation